Plavix, Clopidogrel News

Results from a new analysis of major clinical trial data suggest that the popular clot-busting drug Plavix is nearly equally effective in both men and women.

Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials AstraZeneca announced it has submitted a New Drug Application to the US Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome .

The InVivo Blog has a good article on a controversy in the blood-thinning market.

Aspirin alone is as effective as aspirin plus clopidogrel in keeping coronary artery bypass grafts open during the first year after surgery, according to a study released on Monday.

Analyst Report ) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole.

As the general U.S. population continues to age, more individuals are taking two or more prescribed drugs with Over the Counter drugs.

Main Category: Cardiovascular / Cardiology Also Included In: Clinical Trials / Drug Trials Article Date: 20 Nov 2009 Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular ...

AstraZeneca today announced it has submitted a New Drug Application to the U.S. Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome .

ROCKVILLE,A Md. Patients taking an anticlotting drug should avoid the use of a drug for gastroesophageal reflux disease, the Food and Drug Administration warned Wednesday.

The FDA is updating clopidogrel's label to warn against its concomitant use with the proton-pump inhibitor omeprazole.

How many times have you found yourself at the gym-in a group fitness class, let's say-and you're wondering where went the energy you possessed last night at the club? Why isn't this body conditioning class as high energy as you and your posse cavorting on the dance floor? Of course, if you've ever been in one of fitness guru Heather Cohen's House ...

November 19, 2009 Ticagrelor data presented at the American Heart Association Scientific Sessions Orlando, FL /PRNewswire-FirstCall/ --AstraZeneca today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor ) at the annual American Heart Association Scientific Sessions in Orlando, FL, with ONSET/OFFSET study results ...

The U.S. Food and Drug Administration is warning patients against using the stomach acid reducer Prilosec with the anti-clotting drug Plavix.

FDA notified healthcare professionals of new safety information concerning an interaction between clopidogrel , an anti-clotting medication, and omeprazole , a proton pump inhibitor used to reduce stomach acid.

After years of little progress, three new trials suggest that the latest generation of blood thinners may outperform the old standbys warfarin and clopidogrel .

Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.

Patients who are taking clopidogrel should avoid the concomitant use of omeprazole, a proton-pump inhibitor , because the latter drug diminishes the antiplatelet effects of clopidogrel, FDA announced today.

November 15, 2009 AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome patients, those with ST Segment Elevation Myocardial Infarction .

The Food and Drug Administration say the stomach-soothing drug Prilosec lowers the effectiveness of Plavix by half.

" Two large studies confirmed that an investigational, reversible anti-clotting medication failed to show greater effectiveness than clopidogrel or a placebo for patients undergoing a procedure to open blocked coronary arteries, according to researchers at the Duke Clinical Research Institute.